2026-2034年小分子藥物研發原料藥及CDMO全球市場規模、佔有率、趨勢及成長分析報告

小分子藥物發現原料藥CDMO市場預計將從2025年的528.7億美元成長到2034年的813.9億美元，2026年至2034年的複合年成長率為4.91%。

受製藥生產外包趨勢日益成長的推動，全球小分子藥物研發原料藥（API）合約開發與生產組織（CDMO）市場正經歷強勁成長。藥物研發公司正與合約開發與生產組織（CDMO）合作，以降低成本並縮短藥物研發週期。對複雜小分子藥物和特殊原料藥的需求不斷成長，推動了市場擴張，而日益嚴格的監管要求也促使企業更加依賴經驗豐富的CDMO合作夥伴。

主要促進因素包括新藥核准數量的增加和藥物研發管線的擴展。合約研發生產機構（CDMO）在製程最佳化、規模化生產和法規遵從方面提供專業知識。研發投入的成長和對效率提升的重視正在推動外包活動。此外，對靈活生產能力和先進技術的需求也支撐著該產業的持續成長。

展望未來，隨著製藥公司優先發展策略聯盟，市場預計將進一步成長。連續生產和綠色化學領域的技術進步將提高生產效率。新興市場憑藉其成本優勢和熟練勞動力資源，正成為極具吸引力的外包目的地。隨著小分子療法的不斷創新，合約研發生產機構（CDMO）的角色將日益重要。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章：全球小分子藥物研發原料藥/合約研發生產機構市場：依階段類型分類

• 市場分析、洞察與預測
• 臨床前階段
• 臨床階段
• 商業階段

第5章：全球小分子藥物發現原料藥CDMO市場：依客戶類型分類

• 市場分析、洞察與預測
• 製藥
• 生物技術

第6章：全球小分子藥物研發原料藥/合約研發生產機構市場：依治療領域分類

• 市場分析、洞察與預測
• 心血管疾病
• 腫瘤學
• 神經病學
• 代謝性疾病
• 感染疾病
• 呼吸系統疾病
• 其他

第7章 全球小分子藥物發現原料藥CDMO市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第8章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第9章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Lonza Group Ltd
  • Novo Holdings（Catalent Inc.）
  • Thermo Fisher Scientific Inc
  • Siegfried Holding AG
  • Recipharm AB
  • Cordenpharma International
  • Jubilant Life Sciences（Jubilant Biosys Ltd.）
  • Wuxi AppTec Co. Ltd
  • Merck KGaA
  • Ajinomoto Bio-Pharma Services Inc

The Small Molecule Innovator API CDMO Market size is expected to reach USD 81.39 Billion in 2034 from USD 52.87 Billion (2025) growing at a CAGR of 4.91% during 2026-2034.

The Global Small Molecule Innovator API CDMO Market is experiencing strong growth due to increasing outsourcing trends in pharmaceutical manufacturing. Innovator companies are partnering with Contract Development and Manufacturing Organizations (CDMOs) to reduce costs and accelerate drug development timelines. Rising demand for complex small molecule drugs and specialty APIs is driving market expansion. Growing regulatory requirements also encourage companies to rely on experienced CDMO partners.

Key drivers include the rising number of new drug approvals and expanding pharmaceutical pipelines. CDMOs provide expertise in process optimization, scale-up production, and regulatory compliance. Increasing R&D expenditure and focus on efficiency improvements enhance outsourcing activities. Additionally, the need for flexible manufacturing capabilities and access to advanced technologies supports sustained growth in the sector.

Looking ahead, the market is expected to grow further as pharmaceutical companies prioritize strategic collaborations. Technological advancements in continuous manufacturing and green chemistry will improve production efficiency. Emerging markets are becoming attractive outsourcing hubs due to cost advantages and skilled labor availability. As innovation in small molecule therapeutics continues, the role of CDMOs will remain increasingly critical.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Stage Type

• Preclinical
• Clinical
• Commercial

By Customer Type

• Pharmaceutical
• Biotechnology

By Therapeutic Area

• Cardiovascular Diseases
• Oncology
• Neurology
• Metabolic Disorders
• Infectious Diseases
• Respiratory Disorders
• Others

COMPANIES PROFILED

• Lonza Group Ltd, Novo Holdings Catalent Inc, Thermo Fisher Scientific Inc, Siegfried Holding AG, Recipharm AB, Cordenpharma International, Jubilant Life Sciences Jubilant Biosys Ltd, Wuxi AppTec Co Ltd, Merck KGaA, Ajinomoto BioPharma Services Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL SMALL MOLECULE INNOVATOR API CDMO MARKET: BY STAGE TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Stage Type
• 4.2. Preclinical Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Clinical Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Commercial Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL SMALL MOLECULE INNOVATOR API CDMO MARKET: BY CUSTOMER TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Customer Type
• 5.2. Pharmaceutical Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Biotechnology Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL SMALL MOLECULE INNOVATOR API CDMO MARKET: BY THERAPEUTIC AREA 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Therapeutic Area
• 6.2. Cardiovascular Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Neurology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Metabolic Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. Infectious Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.7. Respiratory Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.8. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL SMALL MOLECULE INNOVATOR API CDMO MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Stage Type
  • 7.2.2 By Customer Type
  • 7.2.3 By Therapeutic Area
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Stage Type
  • 7.3.2 By Customer Type
  • 7.3.3 By Therapeutic Area
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Stage Type
  • 7.4.2 By Customer Type
  • 7.4.3 By Therapeutic Area
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Stage Type
  • 7.5.2 By Customer Type
  • 7.5.3 By Therapeutic Area
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Stage Type
  • 7.6.2 By Customer Type
  • 7.6.3 By Therapeutic Area
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL SMALL MOLECULE INNOVATOR API CDMO INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Lonza Group Ltd
  • 9.2.2 Novo Holdings (Catalent Inc.)
  • 9.2.3 Thermo Fisher Scientific Inc
  • 9.2.4 Siegfried Holding AG
  • 9.2.5 Recipharm AB
  • 9.2.6 Cordenpharma International
  • 9.2.7 Jubilant Life Sciences (Jubilant Biosys Ltd.)
  • 9.2.8 Wuxi AppTec Co. Ltd
  • 9.2.9 Merck KGaA
  • 9.2.10 Ajinomoto Bio-Pharma Services Inc